Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 618-837-0 | CAS number: 92339-11-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- short-term repeated dose toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- February-June 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study was conducted scientifically and in accordance with Good Laboratory Practices.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Guideline:
- other:
- Principles of method if other than guideline:
- Rats were given intravenous injections with iodixanol three times a week for 3 weeks. Sixty male and sixty female CD rats were divided into four group. There were four groups; control (saline), 0.5 gI/kg (low dose), 2.0 gI/kg (mid dose) and 4.0 gI/kg (high dose). At the end of the dosing period, ten males and ten females from each group were sacrificed, and the remaining ten animals from the top dose and control male and female groups were maintained without treatment for a further four weeks and then sacrificed.
- GLP compliance:
- yes
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- intravenous
- Duration of treatment / exposure:
- 3 weeks
- Frequency of treatment:
- 3 times a week
Doses / concentrations
- Remarks:
- Doses / Concentrations:0; 0.5; 2.0; and 4.0 gr I/kg bw)
- No. of animals per sex per dose:
- 0 (gr I/kg bw) 20 animals per sex per dose0.5 (gr I/kg bw) 10 animals per sex per dose2.0 (gr I/kg bw) 10 animals per sex per dose4.0 (gr I/kg bw) 20 animals per sex per dose
- Control animals:
- yes
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Clinical signs associated with treatment were red extremities in all dose groups, and swollen muzzle and feet, gelatinous urine under the cages, and pilo-erection (male rats) at the two highest doses. In addition, high dose animals showed signs of subdued behaviour, collapsed posture, partially closed eyelids and shallow breathing. No treatment related trends were seen in body weight change, food consumption or food utilization. Water consumption was marginally increased in high dose females during week 2, and a marginal reduction was observed in high dose males during the recovery period. Ophthalmoscopy did not reveal any ocular lesions attributable to treatment. There were no effects on haematology and clinical chemistry except for a slight increase in serum albumin levels in high dose animals at week 3, and which was also apparent at the end of the recovery period. During week 3, treated animals tended to have more acidic and concentrated urine than controls. At the end of the recovery period the pH was still slightly lower for the high-dose animals. Kidney weights were increased in mid and high dose animals killed at the end of the treatment period, as well as in the high dose group at the end of the recovery period. At this time, female rats in the high dose group also had elevated liver weights. The kidneys appeared enlarged and pale in some animals in the mid and high dose groups. At the end of the recovery period, this was still apparent in the high dose group. Treatment related cytoplasmic vacuolation was observed in the proximal tubules of the kidneys. This was dose related in the mid and high dose animals, and was more severe in males than in females. Moderate cytoplasmic vacuolation of the proximal tubules was evident in all high dose animals after the four week recovery period. Among low dose animals, the vacuolation was minimal and fine, and was not present in all animals. Cytoplasmic vacuolation in the urothelium of the urinary bladder was also observed in all high dose animals, and in 6/10 males and 4/9 females in the mid dose group at termination. This was not observed in the controls or low dose group. Cytoplasmic vacuolation in the urothelium was also observed in most of the high dose recovery animals. There were no other abnormal findings from the terminal investigations.
- Executive summary:
Rats were given intravenous injections with iodixanol three times a week for 3 weeks. There were four groups; control (saline), 0.5 gI/kg (low dose), 2.0 gI/kg (mid dose) and 4.0 gI/kg (high dose). At the end of the dosing period, ten males and ten females from each group were sacrificed, and the remaining ten animals from the top dose and control male and female groups were maintained without treatment for a further four weeks and then sacrificed. Two female animals (one from the high dose and one from the mid dose group) died during the bleeding procedure on day 21, but this was considered to be unrelated to treatment with the test item. Clinical signs associated with treatment were red extremities in all dose groups, and swollen muzzle and feet, gelatinous urine under the cages, and pilo-erection (male rats) at the two highest doses. In addition, high dose animals showed signs of subdued behaviour, collapsed posture, partially closed eyelids and shallow breathing. No treatment related trends were seen in body weight change, food consumption or food utilization. Water consumption was marginally increased in high dose females during week 2, and a marginal reduction was observed in high dose males during the recovery period. Ophthalmoscopy did not reveal any ocular lesions attributable to treatment. There were no effects on haematology and clinical chemistry except for a slight increase in serum albumin levels in high dose animals at week 3, and which was also apparent at the end of the recovery period. During week 3, treated animals tended to have more acidic and concentrated urine than controls. At the end of the recovery period the pH was still slightly lower for the high-dose animals. Kidney weights were increased in mid and high dose animals killed at the end of the treatment period, as well as in the high dose group at the end of the recovery period. At this time, female rats in the high dose group also had elevated liver weights. The kidneys appeared enlarged and pale in some animals in the mid and high dose groups. At the end of the recovery period, this was still apparent in the high dose group. Treatment related cytoplasmic vacuolation was observed in the proximal tubules of the kidneys. This was dose related in the mid and high dose animals, and was more severe in males than in females. Moderate cytoplasmic vacuolation of the proximal tubules was evident in all high dose animals after the four week recovery period.
Among low dose animals, the vacuolation was minimal and fine, and was not present in all animals. Cytoplasmic vacuolation in the urothelium of the urinary bladder was also observed in all high dose animals, and in 6/10 males and 4/9 females in the mid dose group at termination. This was not observed in the controls or low dose group. Cytoplasmic vacuolation in the urothelium was also observed in most of the high dose recovery animals.
There were no other abnormal findings from the terminal investigations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.